Trial Profile
Post-marketing Clinical Study of Gabapentin Enacarbil -Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment-
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 14 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Nov 2013 New trial record